← Back to Search

Monoclonal Antibodies

UTTR1147A for Ulcerative Colitis

Phase 2
Waitlist Available
Research Sponsored by Genentech, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 2 years
Awards & highlights

Study Summary

This study is evaluating whether a drug may help treat ulcerative colitis and Crohn's disease.

Eligible Conditions
  • Ulcerative Colitis
  • Crohn's Disease

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 2 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 2 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Number of Participants With Adverse Events

Side effects data

From 2021 Phase 2 trial • 396 Patients • NCT04386616
8%
Constipation
7%
Hypokalaemia
7%
Anaemia
6%
Hypertension
5%
COVID-19 pneumonia
5%
Headache
5%
Hypotension
4%
Anxiety
3%
Dry skin
3%
Respiratory failure
2%
Gastric ulcer haemorrhage
2%
Atrial fibrillation
2%
Pneumonia
2%
Septic shock
2%
Multiple organ dysfunction syndrome
2%
Acute myocardial infarction
2%
COVID-19
2%
Acute kidney injury
2%
Hypoxia
2%
Nausea
2%
Pneumothorax
1%
Renal impairment
1%
Cardiac arrest
1%
Cardiac failure
1%
Oxygen saturation decreased
1%
Right ventricular dysfunction
1%
Left ventricular failure
1%
Liver injury
1%
Pneumonia bacterial
1%
Urinary tract infection
1%
Urosepsis
1%
Radius fracture
1%
Aspartate aminotransferase increased
1%
Hypernatraemia
1%
Uterine leiomyoma
1%
Toxic encephalopathy
1%
Confusional state
1%
Haematuria
1%
Acute respiratory failure
1%
Respiratory arrest
1%
Pleural effusion
1%
Pneumomediastinum
1%
Pneumonia aspiration
1%
Pulmonary embolism
1%
Respiratory distress
1%
Shock
1%
Shock haemorrhagic
100%
80%
60%
40%
20%
0%
Study treatment Arm
All Placebo
MSTT1041A
UTTR1147A

Trial Design

1Treatment groups
Experimental Treatment
Group I: UTTR1147AExperimental Treatment1 Intervention
All participants will have the opportunity to receive treatment with UTTR1147A until clinical remission is achieved. Participants will either receive treatment with UTTR1147A or undergo observation depending on disease status, as described in the protocol.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
UTTR1147A
2018
Completed Phase 2
~740

Find a Location

Who is running the clinical trial?

Genentech, Inc.Lead Sponsor
1,539 Previous Clinical Trials
567,546 Total Patients Enrolled
6 Trials studying Ulcerative Colitis
768 Patients Enrolled for Ulcerative Colitis
Clinical TrialsStudy DirectorHoffmann-La Roche
2,199 Previous Clinical Trials
888,359 Total Patients Enrolled
11 Trials studying Ulcerative Colitis
4,047 Patients Enrolled for Ulcerative Colitis

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
An Extension Study to Evaluate the Long-Term Safety and Tolerability of UTTR1147A in Participants With Moderate to Severe Ulcerative Colitis or Crohn's Disease
2019. "An Extension Study to Evaluate the Long-Term Safety and Tolerability of UTTR1147A in Participants With Moderate to Severe Ulcerative Colitis or Crohn's Disease". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03650413.
~23 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top